DUBLIN, June 23, 2015 /PRNewswire/ --

Research and Markets(http://www.researchandmarkets.com/research/w48l6t/global_cancer) has announced the addition of the "Global Cancer Biosimilars Market Opportunity Outlook" report to their offering.

Market introduction of cancer biosimilar is required because they have both high pharmacological and commercialization potential. Chemotherapeutic drugs have dominated the cancer segment for several decade but various new modalities have been introduced in past few years. They are biologic in origin and consist of plethora of therapeutics for numerous cancer indications. They have higher therapeutic efficacy and lesser side effects as compared to chemotherapeutics. Their cost may be high but therapeutic benefits offered by them offers lucrative choice to cancer patients. Some of the cancer biologics are going to lose patent protection and associated rights in coming years. As a result, path would be paved for the market introduction of cancer biosimilars. They have been introduced for several disease indications and their better pharmacological efficacy along with affordable pricing has been widely accepted. Same benefits are also expected to be offered by them to cancer patients due to which significant revenues are expected to be generated by pharmaceutical companies.

Investigators are likely to introduce cancer biosimilars for various indications in coming years that will help them in increasing their market shares. This segment is largely unexplored and offers significant opportunities in future. Their clinical pipeline is quite strong and different products are at various stages of clinical trials. Innovative biosimilar products are expected to be entered in global market as a consequence of strong clinical pipeline. However, their clinical trials are more rigorous as compared to the biologics clinical trials because they are copy molecules. They must satisfy the clinical results when compared to results generated by originator molecules. In this way, their market winding time is increased and due to seriousness of diseases it becomes more important to develop cancer biosimilars with high safety and efficacy levels.

In recent years, biosimilars have received approval in different parts of world due to their comparable pharmacological benefits and cost-effectiveness. It is expected that similar progress would be shown by cancer biosimilars which are at nascent stages of industry life cycle. Amenable guidelines are also expected to be formulated in coming years leading to better commercialization opportunities. These changes are expected to be propelled by escalating cancer patient population and demand for better cancer therapeutics with high cost effectiveness. This scenario shows that cancer biosimilars are going to play an important role at both pharmacological and commercial levels. All these facts show that cancer biosimilars are going to generate significant revenues and have an optimistic future ahead.

"Global Cancer Biosimilars Market Opportunity Outlook" Report Highlight & Findings:

- Introduction & Mechanism of Cancer Biosimilars
- Global Cancer Biosimilars Market Dynamics
- FDA & EMA Guidelines on Development & Marketing of Biosimilars
- Cancer Biosimilars Clinical Pipeline by Company, Indication & Phase
- Cancer Biosimilars Clinical Pipeline: 100 Biosimilars
- Marketed Cancer Biosimilars Clinical Insight
- Marketed Cancer Biosimilars: 15 Biosimilars

Key Topics Covered:

1. Introduction to Cancer Biosimilars

2. Mechanism of Cancer Biosimilars

3. Considerations While Marketing Cancer Biosimilars in Global Market

4. EU & US Regulatory Considerations on Cancer Biosimilars

5. Global Cancer Biosimilars Market Overview

6. Global Cancer Biosimilars Market Dynamics

7. Global Cancer Biosimilars Market Future Prospects

8. EMA Guidelines on Development & Marketing of Biosimilars

9. FDA Guidelines on Development & Marketing of Biosimilars

10. Regulatory Pathways for Development & Marketing of Biosimilars by Country

11. Cancer Biosimilars Clinical Pipeline by Company, Indication & Phase

12. Marketed Cancer Biosimilars Clinical Insight

13. Suspended & Discontinued Cancer Biosimilar Clinical Pipeline

14. Competitive Landscape

- API Co. Ltd
- AXXO
- Actavis
- Aequus BioPharma
- Amega Biotech
- Amgen
- AvesthaGen
- Bio Sidus
- BioSavita
- BioXpress Therapeutics
- Biocad
- Biocon
- Biogenomics
- Boehringer Ingelheim
- CTI BioPharma
- Celltrion
- Dong-A Pharmaceutical
- EPIRUS Biopharmaceuticals
- Glycotope
- Green Cross
- Harvest Moon Pharmaceuticals
- IBioInc
- Inbiopro Solutions
- Ipca Laboratories
- Lupin
- MAbxience
- Momenta Pharmaceuticals
- Pfizer
- PharmaPraxis
- PlantForm Corporation
- Reliance Life Sciences
- Samsung Bioepis
- Teva Pharmaceutical
- Yakult Honsha
- Zydus Cadila

For more information visit http://www.researchandmarkets.com/research/w48l6t/global_cancer

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets